Cargando…

COVID-19 in Adults With Hypertrophic Cardiomyopathy

Background: Individuals with cardiovascular disease are considered high risk for severe COVID-19. However, the clinical impact of COVID-19 in patients with hypertrophic cardiomyopathy (HCM) is unknown. The purpose of this study was to describe the clinical course and outcomes of COVID-19 in patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Arabadjian, Milla E., Reuter, Maria C., Stepanovic, Alexandra, Sherrid, Mark V., Massera, Daniele
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8630625/
https://www.ncbi.nlm.nih.gov/pubmed/34859067
http://dx.doi.org/10.3389/fcvm.2021.745790
_version_ 1784607399700594688
author Arabadjian, Milla E.
Reuter, Maria C.
Stepanovic, Alexandra
Sherrid, Mark V.
Massera, Daniele
author_facet Arabadjian, Milla E.
Reuter, Maria C.
Stepanovic, Alexandra
Sherrid, Mark V.
Massera, Daniele
author_sort Arabadjian, Milla E.
collection PubMed
description Background: Individuals with cardiovascular disease are considered high risk for severe COVID-19. However, the clinical impact of COVID-19 in patients with hypertrophic cardiomyopathy (HCM) is unknown. The purpose of this study was to describe the clinical course and outcomes of COVID-19 in patients with HCM. Methods: This retrospective observational study included adults with HCM and positive PCR/antibody test for SARS-CoV-2 at a large urban hospital system in the New York from January, 2020 to January, 2021. Results: Seventy individuals were included, with a mean (SD) age of 60.1 (15.1) years, 39 (55.7%) of whom were male, and 42 (60%) white. Forty-five (65.3%) patients had obstructive HCM. Hypertension and obesity (BMI ≥ 30) were present in 45 (64.3%) and 37 (52.9%) patients, and the prevalence of atrial fibrillation, obstructive sleep apnea and diabetes was high. Common symptoms of COVID-19 were fever, cough, shortness of breath and fatigue, affecting 33 (47.1%), 33 (47.1%), 28 (40.0%), and 28 (40.0%) patients, respectively. Fourteen (20%) patients were hospitalized. The majority (45 [64.3%] patients) recovered without intervention. Two patients had non-fatal pulmonary embolisms, 1 had atrial fibrillation requiring electrical cardioversion and 1 had acute decompensated heart failure. Three (4.3%) patients required mechanical ventilation, two of whom died (case fatality rate 2.9%). A total of 15 (21.4%) patients were asymptomatic. Conclusions: Our data suggest that in this diverse and high-risk group of patients with HCM, established risk factors for severe COVID-19, such as obesity, may be more important drivers of morbidity and mortality than the presence of HCM alone.
format Online
Article
Text
id pubmed-8630625
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-86306252021-12-01 COVID-19 in Adults With Hypertrophic Cardiomyopathy Arabadjian, Milla E. Reuter, Maria C. Stepanovic, Alexandra Sherrid, Mark V. Massera, Daniele Front Cardiovasc Med Cardiovascular Medicine Background: Individuals with cardiovascular disease are considered high risk for severe COVID-19. However, the clinical impact of COVID-19 in patients with hypertrophic cardiomyopathy (HCM) is unknown. The purpose of this study was to describe the clinical course and outcomes of COVID-19 in patients with HCM. Methods: This retrospective observational study included adults with HCM and positive PCR/antibody test for SARS-CoV-2 at a large urban hospital system in the New York from January, 2020 to January, 2021. Results: Seventy individuals were included, with a mean (SD) age of 60.1 (15.1) years, 39 (55.7%) of whom were male, and 42 (60%) white. Forty-five (65.3%) patients had obstructive HCM. Hypertension and obesity (BMI ≥ 30) were present in 45 (64.3%) and 37 (52.9%) patients, and the prevalence of atrial fibrillation, obstructive sleep apnea and diabetes was high. Common symptoms of COVID-19 were fever, cough, shortness of breath and fatigue, affecting 33 (47.1%), 33 (47.1%), 28 (40.0%), and 28 (40.0%) patients, respectively. Fourteen (20%) patients were hospitalized. The majority (45 [64.3%] patients) recovered without intervention. Two patients had non-fatal pulmonary embolisms, 1 had atrial fibrillation requiring electrical cardioversion and 1 had acute decompensated heart failure. Three (4.3%) patients required mechanical ventilation, two of whom died (case fatality rate 2.9%). A total of 15 (21.4%) patients were asymptomatic. Conclusions: Our data suggest that in this diverse and high-risk group of patients with HCM, established risk factors for severe COVID-19, such as obesity, may be more important drivers of morbidity and mortality than the presence of HCM alone. Frontiers Media S.A. 2021-11-09 /pmc/articles/PMC8630625/ /pubmed/34859067 http://dx.doi.org/10.3389/fcvm.2021.745790 Text en Copyright © 2021 Arabadjian, Reuter, Stepanovic, Sherrid and Massera. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Cardiovascular Medicine
Arabadjian, Milla E.
Reuter, Maria C.
Stepanovic, Alexandra
Sherrid, Mark V.
Massera, Daniele
COVID-19 in Adults With Hypertrophic Cardiomyopathy
title COVID-19 in Adults With Hypertrophic Cardiomyopathy
title_full COVID-19 in Adults With Hypertrophic Cardiomyopathy
title_fullStr COVID-19 in Adults With Hypertrophic Cardiomyopathy
title_full_unstemmed COVID-19 in Adults With Hypertrophic Cardiomyopathy
title_short COVID-19 in Adults With Hypertrophic Cardiomyopathy
title_sort covid-19 in adults with hypertrophic cardiomyopathy
topic Cardiovascular Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8630625/
https://www.ncbi.nlm.nih.gov/pubmed/34859067
http://dx.doi.org/10.3389/fcvm.2021.745790
work_keys_str_mv AT arabadjianmillae covid19inadultswithhypertrophiccardiomyopathy
AT reutermariac covid19inadultswithhypertrophiccardiomyopathy
AT stepanovicalexandra covid19inadultswithhypertrophiccardiomyopathy
AT sherridmarkv covid19inadultswithhypertrophiccardiomyopathy
AT masseradaniele covid19inadultswithhypertrophiccardiomyopathy